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The	inflammatory	kidney	disease	membranoproliferative	glomerulonephritis	type	II	(MPGN2)	is	associat-
ed	with	dysregulation	of	the	alternative	pathway	of	complement	activation.	MPGN2	is	characterized	by	the	
presence	of	complement	C3	along	the	glomerular	basement	membrane	(GBM).	Spontaneous	activation	of	C3	
through	the	alternative	pathway	is	regulated	by	2	plasma	proteins,	factor	H	and	factor	I.	Deficiency	of	either	
of	these	regulators	results	in	uncontrolled	C3	activation,	although	the	breakdown	of	activated	C3	is	dependent	
on	factor	I.	Deficiency	of	factor	H,	but	not	factor	I,	is	associated	with	MPGN2	in	humans,	pigs,	and	mice.	To	
explain	this	discordance,	mice	with	single	or	combined	deficiencies	of	these	factors	were	studied.	MPGN2	did	
not	develop	in	mice	with	combined	factor	H	and	I	deficiency	or	in	mice	deficient	in	factor	I	alone.	However,	
administration	of	a	source	of	factor	I	to	mice	with	combined	factor	H	and	factor	I	deficiency	triggered	both	
activated	C3	fragments	in	plasma	and	GBM	C3	deposition.	Mouse	renal	transplant	studies	demonstrated	that	
C3	deposited	along	the	GBM	was	derived	from	plasma.	Together,	these	findings	provide	what	we	believe	to	
be	the	first	evidence	that	factor	I–mediated	generation	of	activated	C3	fragments	in	the	circulation	is	a	critical	
determinant	for	the	development	of	MPGN2	associated	with	factor	H	deficiency.
Introduction
The complement system is an important part of the innate immune 
system that is composed of a complex group of proteins whose 
main biological functions include host defense, the physiological 
clearance of immune complexes and dying cells, and an adjuvant 
role in the production of immune responses (1). The activation of 
complement is tightly regulated by a sophisticated group of mem-
brane-bound and fluid-phase proteins that function not only to 
prevent tissue damage from autologous complement activation but 
also to prevent depletion of complement proteins (2). In contrast 
to the classical and lectin pathways, whose activation is triggered 
principally by immune complexes and bacterial mannose groups, 
respectively, the alternative pathway of complement activation is in 
a continuous state of low-level activation, resulting in the continu-
ous generation of activated C3 (C3b) in plasma (3). Spontaneous 
activation of C3 in plasma occurs through the “tick-over” pathway, 
which is initiated following the hydrolysis of intact C3 to generate 
C3i (also known as C3[H20]) (4). C3i is able to interact with factors 
B and D to form an enzyme complex (the C3 convertase, C3iBb), 
which can cleave intact C3 to produce C3b, releasing the anaphyla-
toxin C3a. C3b interacts with factors B and D to generate the alter-
native pathway C3 convertase, C3bBb. This convertase causes fur-
ther C3 cleavage and thus amplifies the generation of C3bBb. This 
enables the production of C3b to rapidly increase and is referred to 
as the alternative pathway amplification loop (5). Although these 
C3 convertases will spontaneously decay unless stabilized by pro-
perdin (6), active regulation of alternative pathway activation is 
achieved by 2 plasma proteins, factor H and factor I.
Factor H is an abundant 150-kDa serum glycoprotein that regu-
lates alternative pathway activation. It achieves this by inhibiting 
the formation of the alternative pathway C3 convertases (C3iBb, 
C3bBb) (7, 8). It also promotes the dissociation of these C3 conver-
tases once they have formed, an action termed “decay acceleration 
activity” (8). It is also an essential plasma cofactor in the factor I– 
mediated proteolytic conversion of C3b to iC3b (9). Its importance 
in vivo is illustrated by the complement profile described in indi-
viduals with complete factor H deficiency. In these individuals, 
uncontrolled alternative pathway activation occurs with second-
ary depletion of C3, factor B, and properdin (10).
Factor I is an 88-kDa heterodimeric serine protease with a serum 
concentration of approximately 39–100 μg/ml (11). It functions, 
with cofactor, to inactivate C3b and C4b. The factor I–mediated 
proteolytic inactivation of C3b occurs in 2 steps. Initially, factor I 
cleaves the α-chain of C3b at 2 sites, releasing a 17–amino acid 
peptide termed “C3f” and forming iC3b (12). Essential cofactors 
for this reaction include factor H in the fluid phase (9) and mem-
brane cofactor protein (MCP, CD46) and CR1 on cell surfaces. 
Further degradation of iC3b occurs following the factor I–medi-
ated cleavage of the Arg954-Glu955 bond to produce C3dg and 
C3c. Hence, through its actions on C3b, factor I inhibits alterna-
tive pathway C3 convertase formation, thus limiting alternative 
pathway amplification. Similar to factor H deficiency, complete 
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deficiency of factor I in humans is associated with uncontrolled 
alternative pathway activation with secondary depletion of C3, 
factor B, and properdin (reviewed in ref. 13). Notably, the circulat-
ing C3 in factor I–deficient individuals is in the form of C3b (13), 
indicating an absolute requirement for factor I in the generation 
of C3b metabolites in vivo. Furthermore, secondary reduction in 
factor H levels in factor I–deficient individuals (13–18) has also 
been reported, possibly due to the formation of factor H–C3b 
complexes (16–18).
Uncontrolled alternative pathway activation is associated with 
the inflammatory renal condition membranoproliferative glomer-
ulonephritis type II (MPGN2, also termed “dense deposit disease”) 
(19). MPGN2 is characterized by the presence of intramembranous 
electron-dense material along the glomerular basement membrane 
(GBM) (20) together with staining for C3 (21), C5 (22), and C9 (23) 
along the GBM in the absence of immunoglobulin (24). Complete 
factor H deficiency in humans (25, 26), pigs (27), and mice (28) 
results in spontaneous MPGN2. Furthermore, MPGN2 has been 
reported in an individual with an autoantibody to factor H (29) 
and recently in an individual with a mutation affecting one of the 
complement regulatory domains of factor H (30). Uncontrolled 
alternative pathway regulation and MPGN2 may also occur in 
individuals with normal factor H activity. MPGN2 
is associated with C3 nephritic factor, an IgG auto-
antibody that binds to and stabilizes the alternative 
pathway C3 convertase, resulting in enhanced alter-
native pathway activation. MPGN2 has also been 
reported in families with inherited dysfunctional C3 
molecules, which form C3 convertases resistant to 
physiological inhibition by factor H (31, 32).
Despite the overwhelming evidence linking alter-
native pathway dysregulation and MPGN2, it is 
striking that MPGN2 has never been reported in 
individuals with factor I deficiency (13). The pre-
dominant clinical manifestation in these individuals 
was of increased risk of pyogenic infection, a feature 
shared by individuals with factor H or C3 deficiency 
(13) that is thus likely to be a consequence of the C3 deficiency 
state common to all 3 conditions. To date, glomerulonephritis and 
factor I deficiency has been reported in 3 individuals (14, 15, 33). 
Renal biopsy in one case showed focal segmental glomerulonephri-
tis with glomerular deposition of C4, C3, and immunoglobulins 
(33). In another individual who also had SLE, diffuse proliferative 
class IV lupus glomerulonephritis was present (14). Finally, a third 
case with immune complex glomerulonephritis with glomerular 
IgG and C3 has been reported (15). Thus these renal lesions with 
glomerular immunoglobulin deposition and classical pathway 
activation are pathologically distinct from MPGN2.
To determine why uncontrolled C3 activation in the context of 
factor I deficiency does not result in MPGN2, we have generated 
factor I–deficient (Cfi–/–) mice. These animals displayed uncon-
trolled alternative pathway activation as evidenced by reduced 
C3, factor B, and factor H levels, but did not develop C3 deposi-
tion along the GBM or MPGN2. Hence, the renal phenotype of 
these mice differed significantly from the one reported previously 
in factor H–deficient (Cfh–/–) mice, in which florid C3 deposition 
along the GBM and MPGN2 occurred (28). Remarkably, GBM C3 
deposition did not occur even in mice with combined deficiency of 
factors H and I (Cfh–/–Cfi–/–) despite the presence of uncontrolled 
Figure 1
Generation of Cfi–/– mice. (A) Targeted Cfi locus, target-
ing vector, and structure of the targeted gene. Exons 
are represented by filled boxes, and the neomycin 
resistance gene (Neo) and herpes simplex virus thymi-
dine kinase cassette (HSV-tk) are indicated. Homolo-
gous fragments are indicated by dotted lines. E, EcoRI. 
Double-headed arrows indicate the fragments detected 
on Southern blot analysis of wild-type and recombinant 
alleles after EcoRI digestion of genomic DNA hybridized 
with the 3′ probe (P1, a cDNA probe containing exons 
5 and 6). (B) Amplification of recombinant and wild-type 
alleles using genomic DNA from Cfi–/–, Cfi+/–, and wild-
type mice. Absence of the wild-type allele is seen in the 
Cfi–/– animal. (C) Western blot using nonreducing condi-
tions for serum factor I using crossreactive polyclonal 
anti-human factor I anti-sera. Lane 1 indicates normal 
human sera, lane 2 indicates sera from a factor I–defi-
cient individual. Lanes 3–8 represent mouse sera from 
homozygous, heterozygous, and wild-type mice, as indi-
cated. Absence of the 88-kDa factor I protein (box) is 
evident in the factor I–deficient individual (lane 2) and in 
sera from the Cfi–/– mice (lanes 3 and 4).
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alternative pathway activation. Analysis of plasma C3 activation 
fragments demonstrated that, in the absence of factor I, C3 circu-
lated in the form of C3b. In contrast, in Cfh–/– mice, C3b cleavage 
fragments were detectable in plasma. Reconstitution of factor I 
in Cfh–/–Cfi–/– mice precipitated GBM C3 deposition together with 
the concomitant appearance of C3b cleavage fragments in circula-
tion. Renal transplant experiments confirmed that glomerular C3 
deposition derives from the circulation in Cfh–/– animals. Taken 
together, our observations demonstrate that, during uncontrolled 
alternative pathway activation, factor I–mediated cleavage of C3b 
using cofactors other than factor H is an absolute requirement for 
the development of GBM C3 deposition.
Results
Generation of Cfi–/– mice. We disrupted the gene encoding mouse factor I 
in ES cells by deleting exon 4 of the Cfi gene with a standard gene-
targeting replacement vector (Figure 1A). Homologous recombina-
tion in ES cells was detected by Southern blotting. Mice carrying the 
disrupted allele were screened by PCR (Figure 1B) and were born at 
the expected Mendelian ratios. Absence of factor I was confirmed in 
plasma of Cfi–/– mice using western blotting (Figure 1C). Cfi–/– mice 
were viable and fertile under specific pathogen–free conditions. 
Complement analysis in Cfi–/– mice. Homozygous factor I deficiency 
in humans is associated with secondary reduction in C3 levels, 
with plasma C3 circulating as C3b (13). Hence, we first measured 
plasma C3 in wild-type, heterozygous (Cfi+/–), and Cfi–/– mice (Fig-
ure 2A). As expected, the median plasma C3 level in Cfi–/– mice 
(163.3 mg/l, range 134.5–242.9, n = 20) was significantly lower 
than that seen in either Cfi+/– (291.3 mg/l, range 214–566.7, 
n = 24) or wild-type (358.3 mg/l, range 254.5–439.1, n = 12) ani-
mals (P < 0.001 for Cfi–/– versus wild-type or Cfi+/– mice, Bonferro-
ni’s multiple comparison test). Secondary reduction in factor H 
levels has also been reported in humans with homozygous factor I 
deficiency (13). In keeping with this, factor H levels were signifi-
cantly reduced in the Cfi–/– mice (median 61.9% pooled normal 
wild-type sera, range 42.9%–100.2%, n = 9; Figure 2B) compared 
with both wild-type (median 135.1%, range 96.1%–178.4%, n = 9) 
and Cfi+/– (median 132.9%, range 88.4%–213.5%, n = 16) animals 
(P < 0.001 for Cfi–/– versus wild-type or Cfi+/– mice, Bonferroni’s 
multiple comparison test). Finally, we measured factor B levels 
in Cfi–/– mice (Figure 2C), since reduced levels of factor B have 
been reported in individuals with uncontrolled alternative path-
way activation due to either factor I (13) or factor H (10) defi-
ciency. Significant reduction in plasma factor B levels were seen 
in the Cfi–/– mice (median 12% pooled normal wild-type sera, 
range 9.6%–20.6%, n = 20) compared with both wild-type (median 
74.6%, range 57.1%–130%, n = 12) and Cfi+/– (median 71.3%, range 
52.8%–132%, n = 24) animals (P < 0.001 for Cfi–/– versus wild-type 
Figure 2
Complement profile in Cfi–/– mice. Plasma C3 (A), factor H (B) and factor B (C) 
levels in Cfi–/–, Cfi+/–, and wild-type mice. Horizontal bars denote median values. 
Western blot for mouse C3 using EDTA plasma from wild-type and Cfi–/– mice under 
reducing (D) and nonreducing (E) conditions. In comparison with the molecular 
weight of the intact C3 α-chain in wild-type plasma, the α-chain of C3 derived 
from Cfi–/– plasma ran at approximately 110 kDa (D), consistent with the molecular 
weight of the α′-chain. Under nonreducing conditions C3c was detectable only in 
EDTA plasma from wild-type mice, as evident by the presence of 130-kDa bands 
most easily seen on high exposure (E). EDTA plasma dilutions were 1/1000 for both 
Cfi–/– and wild-type mice.
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or Cfi+/– mice, Bonferroni’s multiple comparison test). Thus the 
plasma complement profile of Cfi–/– mice recapitulated that seen 
in homozygous factor I–deficient humans with reduced plasma 
C3, factor B, and factor H levels.
We next determined the nature of the plasma C3 in the Cfi–/– mice 
by using western blotting of EDTA plasma samples under reducing 
conditions, which enabled identification of the intact and cleaved 
α-chains of C3 (Figure 2D). Murine C3 intact α-chain has a molec-
ular weight of approximately 115 kDa, while the β-chain runs at 
55–60 kDa (34). The molecular weight of the C3 α-chain using 
Cfi–/– plasma was lower than that of the C3 α-chain from wild-type 
plasma and consistent with the molecular weight of the α-chain of 
C3b (also termed “α′-chain”). Notably, no α′-chain fragments were 
demonstrable in EDTA plasma from Cfi–/– mice, consistent with 
the inability of factor I–deficient mouse sera to physiologically 
cleave C3b. Furthermore, while small amounts of C3c (130-kDa 
bands, Figure 2E) were detectable in EDTA plasma from wild-type 
animals, C3c was not detected in plasma from Cfi–/– animals. High-
molecular-weight bands were consistently seen in EDTA plasma 
from Cfi–/– but not wild-type animals, which we postulated were 
due to aggregates of C3b. We therefore concluded that plasma C3 
in the Cfi–/– mice circulates in the form of C3b.
Cfi–/– mice do not develop MPGN2. Uncontrolled C3 activation due 
to complete deficiency of factor H results in spontaneous MPGN2 
in mice (28). We wanted to know whether uncontrolled C3 activa-
tion secondary to murine factor I deficiency resulted in spontane-
ous renal disease. To answer this question, we monitored cohorts 
of wild-type (n = 17), Cfi+/– (n = 29), and Cfi–/– (n = 22) over an 
8-month period, at which point all the animals were sacrificed and 
renal function and histology assessed (Table 1). We selected an 8 
month time period as MPGN2 in Cfh–/– mice was fully penetrant 
by this age (28). Renal function as assessed by plasma urea levels 
and albuminuria did not significantly differ between the experi-
mental groups (Table 1). Indeed, albuminuria was not detectable 
in the majority of the experimental animals regardless of genotype. 
Glomerular histological changes assessed included hypercellular-
ity, mesangial expansion, and the presence of capillary wall thick-
ening. Cfi–/– mice had significant mesangial expansion compared 
with both wild-type and Cfi+/– animals (Table 1). Furthermore, 
deposition of nodular hyaline material was present within the 
mesangium in 10 of the Cfi–/– mice (45.5%) but not in Cfi+/– or wild-
type groups (Table 1 and Figure 3). In contrast, glomerular hyper-
cellularity scores did not differ between the experimental cohorts. 
Notably, light microscopic features of MPGN2, including capillary 
wall double contours, were not present in any of the Cfi–/– mice. 
In summary, Cfi–/– mice did not develop spontaneous glomeru-
lonephritis but, at 8 months, demonstrated increased mesangial 
expansion and, in some animals, areas of mesangial hyalinosis.
Cfh–/– animals have been shown to have florid deposition of C3 
along the GBM, a lesion that precedes the morphological changes 
of MPGN2 (28). Hence, we next examined glomerular C3 staining 
in Cfi–/– mice. Increased glomerular C3 staining was evident in the 
8-month-old Cfi–/– mice (Figure 4A), but the staining pattern was 
mesangial in distribution, in striking contrast to the linear capil-
lary wall staining pattern seen in age-matched Cfh–/– animals (Fig-
Table 1
Renal function and histological analysis in 8-month-old (129/Sv × C57BL/6) Cfi–/– mice
	 Renal	function	 Renal	histology
Mouse	 n	 Plasma	ureaA	 Albuminuria	 Glomerular	hypercellularity	 Mesangial	expansion	 MH	 GBM	DC
	 	 mmol/l	(range)	 μg/ml	(range)	 %	Pos	(n)	 n	 0	 I	 II	 III	 IV	 0	 I	 II	 III	 %	Pos	(n)	 %	Pos	(n)
WT 17 14.9 (11.1–26) 0 (0–746.7) 17.6 (3/17) 17 5 7 4 0 1 12 3 2 0 0 0
Cfi+/– 29 13.3 (8.2–30.4) 0 (0–684.4) 21.4 (6/28) 29 14 8 4 3 0 22 6 1 0 0 0
Cfi–/– 22 15.3 (8.1–26.7) 0 (0–99.7) 14.3 (3/21) 22 7 12 2 1 0 3B 8 8 3 45.5% (10) 0
AValues represent median. BP < 0.001 for Cfi–/– vs. wild-type or Cfi+/–, Bonferroni multiple comparisons test. Pos, positive; MH, Mesangial hyalinosis; GBM 
DC, GBM double contours.
Figure 3
Light microscopic appearances of mesangial hyalinosis in 8-month-
old Cfi–/– mice. PAS-stained glomerular sections from 8-month-old 
wild-type (A) and Cfi–/– mice (B and C). The glomerulus from the wild-
type mouse had normal appearances. In contrast, areas of mesan-
gial expansion with a nodular hyaline appearance were evident in the 
Cfi–/– mice (arrows). Original magnification, ×40 (B); ×100(A and C).
research article
612	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 118   Number 2   February 2008
ure 4B). Glomerular C3 staining was identical in Cfi+/– and wild-
type animals (Figure 4, C and D). Quantification of the glomerular 
C3 staining from a representative number of the 8-month-old 
cohort animals (Figure 4E) confirmed significantly increased glo-
merular C3 in the Cfi–/– mice (median 31.5 arbitrary fluorescence 
units [AFU], range 24–51, n = 12) compared with wild-type (medi-
an 21.5 AFU, range 12–40, n = 8) or Cfh+/– (median 17.5 AFU, range 
9–30, n = 10) animals (P < 0.05 for Cfi–/– versus Cfi+/– mice and Cfi–/– 
versus wild-type mice, Bonferroni’s multiple comparison test). 
In contrast, glomerular IgG staining did not differ between the 
experimental animals (data not shown). In summary, Cfi–/– mice 
developed increased mesangial C3 staining but not deposition of 
C3 along the GBM. 
Factor I is an absolute requirement for GBM C3 deposition and the devel-
opment of MPGN2 in Cfh–/– mice. Unlike factor H deficiency, uncon-
trolled C3 activation due to deficiency of factor I did not result in 
spontaneous GBM C3 deposition. This led us to hypothesize that 
during uncontrolled C3 activation, factor H protects the GBM 
from C3 deposition. To investigate this we examined glomerular 
C3 staining patterns in Cfi–/– mice with either heterozygous (Cfh+/–
Cfi–/–) or homozygous (Cf h–/–Cfi–/–) deficiency of factor H (Figure 
5A). Cfh+/–Cfi–/– animals had glomerular C3 staining patterns iden-
tical to those of mice deficient in factor I alone, indicating that 
haploinsufficiency of factor H did not influence glomerular C3 
staining in Cfi–/– mice. Unexpectedly, Cf h–/–Cfi–/– mice, in marked 
contrast to the GBM staining pattern seen in factor H–deficient 
animals (Figure 4B), demonstrated glomerular C3 staining equiva-
lent to that seen in mice deficient in factor I alone (Figure 5A). 
Thus factor I deficiency completely prevented accumulation of C3 
along the GBM in Cfh–/– mice.
Since GBM C3 deposition precedes the morphological changes 
of MPGN2 in Cf h–/– mice, we predicted that the lack of GBM C3 
deposition in the Cf h–/–Cfi–/– animals would prevent the develop-
ment of MPGN2. Hence we examined glomerular histology in 
8-month-old Cfh–/–Cfi–/– mice (n = 5). Unlike 8 month old Cfh–/– 
mice, no light microscopic evidence of MPGN2 was present in the 
Cf h–/–Cfi–/– animals (data not shown). Hence, factor I deficiency 
completely prevented the development of MPGN2 in Cfh–/– mice. 
Nature of circulating C3 activation products in vivo in the absence of 
factor I and/or factor H. A predicted difference between factor H and 
factor I deficiency is the nature of the C3 activation products that 
can be formed. In the absence of factor I, physiological cleavage of 
the α-chain of C3b is prevented, while in the absence of factor H, 
factor I may cleave C3b using alternative cofactors. Hence, we next 
determined C3 levels and C3 activation products present in the 
plasma of the Cfh–/– and Cfi–/– mice (Figure 5, B, D, and E). Median 
levels of plasma C3 levels in both Cfi–/– and Cfh–/– mice were signifi-
cantly reduced compared with wild-type mice (Figure 5B). However, 
the median C3 level in the Cfi–/– mice was significantly higher than 
that seen in Cfh–/– animals. Moreover, mice with combined defi-
ciency of factors H and I also had a median C3 level that was sig-
nificantly higher than that seen in mice with deficiency of factor H 
alone but was not different from that seen in the Cfi–/– animals. 
Importantly, in mice with single or combined deficiency of factors 
H and I, factor B levels always remained low, indicating that fac-
tor B consumption occurred irrespective of whether uncontrolled 
alternative pathway was due to factor H or factor I deficiency (Fig-
ure 5C). We next assessed the nature of the circulating C3 by west-
ern blotting under reducing conditions using EDTA plasma from 
Cfh–/–, Cfi–/–, and Cfh–/–Cfi–/– mice (Figure 5D). This analysis showed 
that, even on prolonged exposure of the blot, cleavage of the C3 
α′-chain to produce α′-chain fragments was only evident in EDTA 
plasma from Cfh–/– mice (Figure 5D). Notably, in mice with factor I 
deficiency either alone or in combination with factor H deficiency, 
the molecular weight of the α-chain was reduced compared with 
wild-type α-chain, consistent with the molecular weight of the C3 
α′-chain of C3b. High-molecular-weight bands were detected in 
the Cfi–/– and Cfh–/–Cfi–/– EDTA plasma, which we postulated were 
due to the formation of C3b oligomers, since these were not seen 
in the wild-type animals (excluding oligomers of intact C3) and 
were not seen in C3–/– EDTA plasma control (excluding nonspe-
cific antibody binding). Cleavage of the C3b α′-chain from sera 
from either the Cfi–/– or Cfh–/–Cfi–/– mice was readily achieved by 
incubating the respective sera with C3-deficient mouse sera (as a 
source of autologous factors I and H), generating an identically 
sized α-chain cleavage fragment (Figure 5D) that could be seen 
using EDTA plasma from a Cfh–/– animal (Figure 5D). To deter-
mine whether C3c in addition to iC3b was present in EDTA plas-
ma from Cfh–/– mice, we performed western blotting under nonre-
ducing conditions. Under these conditions, C3c was demonstrable 
in the EDTA plasma from the Cfh–/– animals (Figure 5E). Hence, 
together these findings demonstrated that the critical difference 
between Cfh–/– and Cfh–/–Cfi–/– animals was the nature of the circu-
lating C3 activation fragment: in Cfh–/– mice, formation of iC3b 
and C3c occurred, while in both Cfi–/– and Cfh–/–Cfi–/– animals, C3 
circulated in the form of C3b.
Infusion of serum containing factor I to mice with combined deficiency of 
factor H and factor I triggers GBM C3 deposition in vivo. To further dem-
Figure 4
Glomerular C3 staining in 8-month-
old Cfi–/– mice. (A) Increased glo-
merular C3 staining was present 
in Cfi–/– mice that was mesangial in 
distribution, in contrast to the linear 
capillary wall staining pattern seen 
in Cfh–/– mice (B). Glomerular C3 
staining in Cfi+/– mice (C) was iden-
tical to that seen in age-matched 
wild-type animals (D). Quantitative 
immunofluorescence for glomerular 
C3 from 8-month-old Cfi–/–, Cfi+/–, 
and wild-type mice (E). Original 
magnification, ×40.
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onstrate in vivo that deficiency of factor I abolished accumulation 
of C3 along the GBM in Cfh–/– mice, we examined glomerular C3 
staining in Cfh–/–Cfi–/– animals reconstituted with mouse factor I. 
To achieve this, we administered injections of sera deficient in 
both factor H and C3 (obtained from Cfh–/–C3–/– mice) as a source 
of autologous factor I to Cfh–/–Cfi–/– mice. Follow-
ing serial injections of Cfh–/–C3–/– sera, we observed 
first that there was a rapid decrease in plasma C3 
levels (Figure 6A) together with the appearance of 
C3 α-chain fragments in the circulation (Figure 
6B). Importantly, 72 hours after serial injections 
of Cfh–/–C3–/– sera to Cf h–/–Cfi–/– animals, florid 
glomerular C3 staining was evident in a capillary 
wall distribution consistent with GBM C3 deposi-
tion (Figure 6C) and identical in pattern to that 
seen in unmanipulated Cfh–/– mice (Figure 4B).
Secondly, we examined glomerular C3 staining 
in Cfh–/– mice with heterozygous deficiency of fac-
tor I (Figure 6D). In these animals, glomerular C3 
staining was identical to that seen in mice with 
factor H deficiency alone. Furthermore, unlike 
Cfh–/–Cfi–/– mice that had C3 levels comparable 
with those seen in the Cfi–/– mice, the Cf h–/–Cfi+/– 
animals had markedly reduced C3 levels (median 
17.8 mg/l, range 11.5–29.2, n = 10) comparable 
with mice deficient in Cfh–/– alone.
Hence, analysis of glomerular C3 staining pat-
terns in Cfh–/–Cfi–/– mice reconstituted with factor I 
and in Cfh–/– mice with heterozygous factor I defi-
ciency confirmed that factor I is critically required for GBM C3 
deposition in Cfh–/– mice.
The C3 deposited along the GBM in factor H–deficient mice derives from 
the circulation. The absolute requirement of factor I for the develop-
ment of GBM C3 deposition in the Cfh–/– mice suggested that the 
Figure 5
Glomerular C3 staining and complement profile in 
mice with deficiency of both factor H and factor I. 
(A) Glomerular C3 staining in Cfi–/– mice with nor-
mal (Cfh+/+), heterozygous (Cfh+/–), and homozygous 
(Cfh–/–) factor H genotypes. A mesangial staining 
pattern was evident in the glomeruli of the Cfi–/– mice 
regardless of factor H genotype. Note the marked 
contrast in glomerular C3 staining pattern between the 
Cfi–/–Cfh–/– mice and that seen in mice with factor H 
deficiency alone (Figure 4B). Original magnifica-
tion, ×40. Plasma C3 (B) and factor B (C) levels in 
Cfi–/– mice with heterozygous and homozygous factor 
H deficiency. Horizontal bars denote median values. 
(D) Western blot for C3 from Cfi–/– and Cfi–/–Cfh–/– 
mice under reducing conditions. On this high-expo-
sure α-chain, fragments were only present in the 
Cfh–/– EDTA plasma (lane 4). The lower molecular 
weight of the α′-chain (lanes 2, 3, and 4) compared 
with the intact α-chain (lane 1) was also evident. 
Also shown are sera from Cfi–/– and Cfi–/–Cfh–/– mice 
before and after incubation with murine sera deficient 
in C3 (as a source of autologous factors I and H). 
Note that in both Cfi–/– and Cfi–/–Cfh–/– mice, complete 
cleavage of the α′-chain occurred with the concomi-
tant appearance of the 43-kDa α′-chain fragment that 
was evident in unmanipulated EDTA plasma taken 
from a Cfh–/– animal (lane 4). (E) Under nonreducing 
conditions C3c was detectable in EDTA plasma from 
Cfh–/– and wild-type mice, but not from Cfi–/– mice. 
Note that EDTA plasma dilutions were 1/1000 for 
wild-type and Cfi–/– mice and 1/100 for Cfh–/– mice.
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source of the GBM C3 was from the circulation and not derived 
from local renal C3 synthesis. To test this hypothesis, we conduct-
ed renal transplants in the Cfh–/– animals (Figure 7). We first trans-
planted kidneys from wild-type mice into Cfh–/– recipients and then 
examined glomerular C3 staining 6 weeks later. C3 staining along 
the GBM was seen in the wild-type kidneys transplanted into Cfh–/– 
recipients although the intensity of staining was not as marked 
as that seen in a Cfh–/– kidney transplanted into a Cf h–/– recipient. 
We hypothesized that this could be due to partial glomerular C3 
regulation by local factor H synthesis within the wild-type donor 
kidney, which has been previously demonstrated (35). Hence, we 
also examined glomerular C3 staining in a kidney from a donor 
with combined deficiency of C3 and factor H (Cfh–/–C3–/–) that had 
been transplanted into a Cfh–/– host. Glomerular C3 staining in 
this kidney demonstrated florid capillary wall deposition of C3, 
equivalent to that seen in unmanipulated Cfh–/– kidneys. Notably, 
no abnormal glomerular C3 staining was demonstrable in a wild-
type donor kidney transplanted into a wild-type recipient. Hence, 
we conclude that GBM C3 deposition in Cf h–/– mice is entirely 
derived from the circulation.
Discussion
We have generated factor I–deficient mice and demonstrated that 
these animals have reduced plasma levels of C3, together with 
reduced plasma levels of the alternative pathway activation pro-
tein, factor B. In addition, C3 circulated as C3b in these animals 
with no in vivo evidence of formation of C3 metabolites (iC3b, 
C3c, C3dg). These features are characteristic of the complement 
abnormalities reported in humans with homozygous factor I defi-
ciency (13). An important difference between factor I and factor H 
deficiency is the fate of plasma C3b: factor I–mediated cleavage 
of C3b to form iC3b, C3c, and C3dg may occur in factor H–defi-
cient but not factor I–deficient individuals. In factor I–deficient 
individuals, plasma C3 circulates predominantly as C3b, while 
C3b metabolites such as C3dg are not detectable in plasma (13). 
In contrast, studies of humans with complete absence of factor H 
have demonstrated that iC3b (36), C3c (37), and C3dg (37, 38) are 
present in the circulation in addition to C3dg present on erythro-
cytes (25). In both humans (9) and mice (39), the factor I–mediated 
cleavage of fluid-phase C3b in vitro does not occur in the absence 
of a cofactor such as factor H. Hence, the presence of C3b metabo-
lites in factor H–deficient human sera is most likely a consequence 
of alternative factor I cofactors in circulation. These include CR1 
on erythrocytes (36, 37), plasma factor H–like protein 1 (38), and 
plasma factor H–related protein 5 (40). Our data demonstrated 
that there was no evidence of C3b fragments in EDTA plasma in 
mice with factor I deficiency, irrespective of the factor H genotype. 
In contrast, in the Cf h–/– mice, iC3b and C3c could be detected in 
EDTA plasma, indicating that murine C3b can be cleaved by fac-
tor I in the absence of factor H. In this regard it is notable that in 
factor H–deficient pigs, which completely lack circulating plasma 
factor H due to a point mutation that prevented protein secretion 
(41), evidence of C3c formation was readily demonstrable in plas-
ma (27). In fact, this observation was presented as indirect evidence 
to exclude factor I dysfunction as a cause of the uncontrolled C3 
activation in these animals (27). Hence, analogous to human fac-
tor H deficiency, in both pigs and mice, factor I–mediated cleavage 
of C3b in plasma can proceed in the absence of factor H through 
the use of alternative cofactors.
In both Cfh–/– mice (28) and factor H–deficient pigs (42), C3 depo-
sition along the GBM in the absence of immunoglobulin was the 
first glomerular abnormality, preceding both the appearance of 
electron-dense changes along the GBM and morphological changes 
of MPGN2. In contrast, mice deficient in factor I did not develop 
GBM C3 deposition. In these animals glomerular C3 staining was 
abnormal but clearly localized to the mesangium. By 8 months of 
Figure 6
Administration of sera containing factor I to Cfh–/–
Cfi–/– mice. Following injections of sera from Cfh–/–
C3–/– mice (used as a source of autologous factor I), 
plasma C3 levels fell rapidly to levels comparable with 
those seen in mice with factor H deficiency alone (A). 
Furthermore, α′-chain fragments became evident in 
plasma (B). Finally, at the end of the experiment, florid 
glomerular C3 staining identical to that seen in unma-
nipulated Cfh–/– mice was present in the reconstituted 
animals, in marked contrast to the mesangial C3 stain-
ing present in the noninjected Cfh–/–Cfi–/– control mice 
(C). Consistent with these data was the observation 
that Cfh–/– mice with heterozygous factor I deficiency 
had identical glomerular C3 staining to that seen in 
Cfh–/– animals (D). Original magnification, ×40.
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age, significantly increased mesangial expansion was evident on 
light microscopy in these animals, together with, in some mice, 
nodular hyaline deposits in the mesangium. However, there was 
no evidence of renal impairment or glomerulonephritis, including 
MPGN2. In this respect, it is notable that mesangial deposits of C3 
in the absence of mesangial proliferation has recently been noted in 
6 individuals, 4 of whom harbored heterozygous mutations affect-
ing either factor H or factor I (43). We have not detected any evi-
dence of spontaneous renal pathology in mice with heterozygous 
deficiency of either factor I (as discussed in this study) or factor H 
(28). However, it is clearly possible that, in the presence of other pre-
disposing factors to glomerular inflammation, the presence of such 
mutations could influence the pattern of glomerular injury.
We hypothesized that circulating or locally produced factor H in 
the Cfi–/– mice could function to protect the GBM from C3b depo-
sition and hence the development of MPGN2. Hence, we generated 
mice with combined deficiency of these regulators. Homozygous 
combined deficiency of factor H and I has never been reported 
in humans, and hence the generation of the Cf h–/–Cfi–/– mice rep-
resented a unique in vivo scenario in which we could test this 
hypothesis. Mesangial C3 staining developed in Cf h–/–Cfi–/– mice, 
equivalent to that seen in mice deficient in factor I alone, but there 
was no evidence of GBM C3 deposition. Furthermore, in 8-month-
old Cfh–/–Cfi–/– mice there was no light microscopic evidence of 
MPGN2. This clearly demonstrated both that in Cfi–/– mice factor H 
was not responsible for the lack of GBM C3 deposition and that 
factor I was a critical requirement for GBM C3 deposition and sub-
sequent MPGN2 in Cfh–/– mice.
To test the hypothesis that factor I was essential for the devel-
opment of GBM C3 deposition in Cf h–/– mice, we administered 
injections of sera deficient in both C3 and factor H, as a source 
of autologous factor I, to Cfh–/–Cfi–/– mice. This resulted in fur-
ther reduction in plasma C3 levels (equivalent to those seen in 
Cf h–/– mice), and critically, the development of florid linear cap-
illary wall C3 deposition. Consistent with this data, unmanipu-
lated Cf h–/– mice with heterozygous factor I deficiency devel-
oped glomerular GBM C3 deposition identical to that seen in 
Cfh–/– mice. To determine whether the GBM C3 deposition in 
Cfh–/– mice derived from the circulation and not from local renal 
synthesis of C3, we performed renal transplantation experiments 
in Cf h–/– mice. These experiments demonstrated that both wild-
type donor kidneys and donor kidneys from mice with combined 
deficiency of C3 and factor H developed linear capillary wall C3 
staining when transplanted into the Cf h–/– mice, confirming that 
the glomerular C3 in the Cf h–/– mice is derived from the circula-
tion. These data demonstrated that not only is factor I an essen-
tial requirement for the development of GBM C3 deposition in 
Cf h–/– mice but also that the GBM C3 deposition in Cf h–/– mice 
derives from the circulation.
It is striking that the median C3 levels in the Cfi–/– mice were 
significantly higher (approximately 10-fold; Figure 5) than those 
seen in the Cfh–/– mice. Factor H deficiency in humans is associated 
with markedly reduced C3 levels. For example, in cases in which 
factor H is completely undetectable in plasma, C3 levels are often 
below the lower limit of assay detection (36, 37, 44), equating to 
levels of less than 10 mg/l (36). In contrast, in patients with homo-
zygous factor I deficiency, C3 levels, although invariably reduced, 
are typically in the range of 15%–30% (13) and may reach 50% of 
normal values (15, 18). Thus the greater reduction in C3 levels seen 
in Cfh–/– mice compared with the reduction seen in Cfi–/– mice par-
allels that seen in the respective human deficiencies.
The presence of secondary reduction in factor H levels, a consis-
tent feature of human factor I deficiency, has been thought to be a 
consequence of increased binding of C3b to circulating factor H to 
form C3b–factor H complexes (16–18), which are then presumably 
removed from the circulation. We hypothesized that this may be 
one mechanism that limits the production of C3b in the setting of 
factor I deficiency. However, our data demonstrated that C3 levels 
were reduced to similar levels in Cfi–/– and Cfh–/–Cfi–/– mice. Further-
more, the degree of factor B depletion in these animals was also 
identical, indicating that the presence of factor H was not limiting 
alternative pathway activation in the Cfi–/– mice. This observation 
would also suggest that the formation of the alternative pathway 
convertase C3bBb, with consequent consumption of factor B, 
was occurring to a similar extent in both deficiency states. Plasma 
C3 levels are clearly influenced by both C3 synthetic rate and the 
degree of C3 activation. Notably, depression of C3 synthesis during 
hypocomplementemia has been reported in humans and was most 
pronounced in patients with circulating C3dg (45). In contrast, 
C3 synthesis was not altered in a patient with hypocomplement-
emia due to factor I deficiency, which also prevented the genera-
tion of plasma C3dg (45). Hence, the difference in the magnitude 
of depression of plasma C3 between factor H and factor I deficiency 
may be a consequence of differential C3 synthetic rates.
Taken together, our data suggest that during uncontrolled 
alternative pathway activation it is the nature of the plasma C3 
activation product that critically determines whether GBM C3 
deposition develops. In factor I deficiency, in which only C3b is 
Figure 7
Glomerular C3 staining in renal transplant studies in Cfh–/– mice. Kid-
neys from wild-type (A), Cfh–/–C3–/– (B), and Cfh–/– (D) mice were trans-
planted into Cfh–/– animals. Linear capillary wall C3 staining developed 
in both wild-type (A) and Cfh–/–C3–/– (B) kidneys transplanted into 
Cfh–/– animals. Transplantation of a wild-type kidney into a wild-type 
recipient did not result in abnormal glomerular C3 staining (C), and 
transplantation of a Cfh–/– kidney into a Cfh–/– recipient did not alter the 
abnormal glomerular C3 staining seen in unmanipulated Cfh–/– kidneys 
(D). Original magnification, ×40.
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produced, no GBM C3 deposition occurs, but increased mesangial 
C3 staining is present. In contrast, factor H deficiency is accompa-
nied by florid GBM C3 deposition together with the presence of 
circulating C3b metabolites. One could postulate that C3b metab-
olites (iC3b, C3c, C3dg) might have an increased affinity for the 
GBM compared with C3b. In human MPGN2 associated with C3 
nephritic factor, complete cleavage of C3 is typical with the forma-
tion of C3c and C3dg in circulation (46). Lack of murine reagents 
that can unequivocally differentiate between C3b, iC3b, C3c, and 
C3dg has impeded the definitive characterization of the nature of 
the C3 activation fragments present along the GBM in Cfh–/– mice. 
However, our present data would strongly suggest that the GBM 
C3 in these animals, at least initially, is comprised of iC3b and/or 
its metabolites, C3c and C3dg. Additional support for this derives 
from the observation that iC3b was identifiable in glomeruli iso-
lated from Cfh–/– mice by laser capture microdissection (47).
In contrast to C3b, iC3b and its metabolites cannot interact 
with factor B or properdin to form a C3 convertase. In this respect 
it is notable that in the factor H–deficient pigs the GBM C3 did 
not stain for either factor B or properdin (42) Furthermore, C3 
deposits in the paramesangial areas in human MPGN2 appear to 
consist only of C3c (22), and properdin is usually absent in the 
GBM deposits (22, 48). Glomerular deposits consisting of iC3b, 
C3c, or C3dg would not allow local formation of C5 convertase, 
yet we have previously reported that GBM C9 staining is present 
in Cfh–/– mice (28). Terminal complement complex (TCC), C5, and 
C6 were present in the factor H–deficient pigs (42). Furthermore, 
in some renal biopsy specimens from humans with factor H defi-
ciency, staining along the GBM for TCC has been demonstrated 
(25). Moreover, in some human MPGN2 renal biopsies, both C9 
(23) and, in rapidly progressing disease, C5 have been detected 
(22). We reasoned that this may be explained by the fact that the 
TCC is formed in the circulation and then deposited along the 
GBM. Indirect support for this hypothesis derives from the obser-
vation that in the factor H–deficient pigs, glomerular TCC invari-
ably costained for vitronectin (42). In addition, these animals had 
increased plasma levels of TCC (42), and plasma C5 activation has 
also been demonstrated in Cfh–/– mice (28).
There remains no definitive therapy for MPGN2 (19). We have 
previously shown that the inability to inhibit C5 activation ame-
liorated but did not prevent the development of MPGN2 in Cfh–/– 
mice (49). In the present study, we have shown that the metabo-
lism of C3b in the circulation is an absolute requirement for the 
initiation of GBM C3 deposition in the Cf h–/– mice. This raises 
the intriguing and novel possibility that GBM C3 deposition sec-
ondary to alternative pathway dysregulation could be prevented, 
regardless of etiology, by strategies that either prevent proteolytic 
cleavage of C3b or sequester its metabolites in the circulation.
Methods
Animals. Cfh–/– mice were developed as previously reported (28). Generation 
of mice with combined deficiency of factors H and I were generated by 
intercrossing Cf h–/– and Cfi–/– mice. The genotyping of the Cfh–/– mice has 
been previously described (28). All procedures were performed in accor-
dance with institutional guidelines. Animal studies were performed under 
a Project Licence issued by the United Kingdom Home Office.
Generation of Cfi–/– mice.	We generated mice with a disrupted Cfi locus by 
homologous recombination in ES cells. In the targeting gene locus, exon 4 
of the murine factor I gene was replace by a positive selectable marker, 
the neomycin-resistant gene (pMC1NeoPolyA; Stratagene). The neomy-
cin-resistance cassette was flanked by two 2-kb regions of target homol-
ogy, and a negative selectable marker (HSV-tk) was inserted outside the 
region of homology. We screened ES cells by Southern blotting analysis of 
EcoRI-digested genomic DNA using a 3′ external cDNA probe. Germline 
transmission of the recombinant ES cells was achieved. Heterozygotes were 
interbred to obtain viable (129/Sv × C57BL/6) mice that were homozy-
gous for the disrupted allele. Genotyping of the Cfi–/– mice was performed 
using the following primers on genomic DNA isolated from tail digests: 
5′-GTATGTCACGAACACCCCTGC-3′  (FI4D-), 5′-GAGGGGAT-
CAATTCTCTAGAGCT-3′ (FINeo1-), and 5′-GAGATCAACCACGCGAG-
GCTT-3′ (KFI+). For the spontaneous phenotypic analysis (129 × C57BL/6), 
homozygous factor I–deficient mice together with littermate wild-type and 
heterozygous factor I–deficient animals were used.
Measurement of C3, factor H, and factor B levels and western blotting of plasma 
factor I and C3.	Factor H levels were measured by ELISA using a goat anti-
rat FH antibody (a gift from M. Daha, Leiden University Medical Center, 
Leiden, The Netherlands) and a rabbit anti-mouse FH antibody (a gift 
from S. Rodriguez de Cordoba, Centro de Investigaciones Biológicas, 
Madrid, Spain). Factor B levels were measured by ELISA using a goat 
anti-human factor B (Diasorin) and a monoclonal anti-mouse factor B 
antibody (a gift from J. Thurman, University of Colorado Health Sci-
ences Center, Denver, Colorado, USA). Samples for factor H and factor B 
were quantified by reference to a standard curve generated using normal 
wild-type mouse serum. C3 levels were measured by ELISA using a goat 
anti-mouse C3 antibody (MP Biomedicals). Results were quantified by 
reference to a standard curve generated from acute-phase sera contain-
ing a known quantity of C3 (Calbiochem). For western blotting of serum, 
murine factor I was detected using a crossreactive polyclonal goat anti-
body against human factor I (Quidel), and C3 was detected using goat 
anti-mouse C3 antibody (MP Biomedicals).
Histological studies. For light microscopy, kidneys were fixed in Bouin’s 
solution and sections stained with PAS reagent. For immunofluorescence 
studies, kidneys were snap-frozen. Glomerular histology was graded as fol-
lows: grade 0, normal; grade I, hypercellularity in 10%–25% of glomeruli; 
grade II, hypercellularity in 25%–50% of glomeruli; grade III, hypercellular-
ity in 50%–75% of glomeruli; grade IV, glomerular hypercellularity in >75% 
or crescents in >25% of glomeruli. Specific changes of MPGN were the pres-
ence of GBM double contours and capillary wall thickening. Histological 
analysis was performed in a blinded fashion, and 50 glomeruli per section 
were analyzed. FITC-conjugated goat anti-mouse C3 (ICN Pharmaceuti-
cals) and FITC-conjugated goat anti-mouse IgG (Sigma-Aldrich) were used 
at dilutions of 1/100 and 1/200, respectively, in phosphate-buffered saline. 
FITC-conjugated goat immunoglobulins were used as a control for these 2 
antibodies. Quantitative immunofluorescence studies were performed as 
previously described (50), and results are expressed as AFU.
Assessment of renal function. Urinary albumin was measured by radial 
immunodiffusion using a rabbit anti-mouse albumin antibody (Biogen-
esis) and purified mouse albumin (Sigma-Aldrich) as standards, as previ-
ously described (50). Serum urea was measured using a UV method kit 
(R-Biopharm Rhone) according to the manufacturer’s instructions.
Administration of sera containing factor I.	For these experiments serum 
was obtained from mice with combined deficiency of factor H and C3 
(Cfh–/–C3–/–). An initial intravenous injection of 200 μl of sera was adminis-
tered to Cfh–/–Cfi–/– animals, and then a further 400 μl of sera was injected 
intraperitoneally at 24 and 48 hours.
Renal transplant studies. The renal transplantation procedure has been 
described previously (51). Briefly, the left kidney was removed from 6- to 
8-week-old donor mice and preserved in cold saline. The right kidney was 
removed from recipient mice and the donor kidney transplanted with end-
to-side anastomoses of the donor renal vein to the inferior vena cava and 
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the donor aortic cuff to the aorta. Ureter-to-bladder anastomosis was per-
formed to reconstruct the urinary tract. Mice were sacrificed 4–6 weeks 
after transplant procedure, and renal histology was assessed.
Statistics. The Mann-Whitney U test was used for comparison of 2 groups, 
while for analysis of 3 or more groups, Bonferroni’s multiple comparisons 
test was used. Data were analyzed using GraphPad Prism version 3.0 for 
Windows (GraphPad Software).
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